We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Fusion Antibodies Plc | LSE:FAB | London | Ordinary Share | GB00BDQZGK16 | ORD 4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.45 | 6.98% | 6.90 | 1,630,765 | 09:10:38 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 6.70 | 7.10 | 7.00 | 6.50 | 6.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1.14M | -2.23M | -0.0233 | -2.96 | 6.15M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:59:40 | O | 7 | 6.977 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 08/5/2025 | 07:00 | UK RNS | Fusion Antibodies PLC Investor presentation |
| 07/5/2025 | 07:00 | UK RNS | Fusion Antibodies PLC Issue of shares to non-executive directors |
| 06/5/2025 | 10:53 | UK RNS | Fusion Antibodies PLC Director/PDMR Shareholding |
| 06/5/2025 | 10:38 | UK RNS | Fusion Antibodies PLC Holding(s) in Company |
| 06/5/2025 | 07:00 | UK RNS | Fusion Antibodies PLC Trading update |
| 30/4/2025 | 17:00 | UK RNS | Fusion Antibodies PLC Total Voting Rights |
| 24/4/2025 | 07:00 | UK RNS | Fusion Antibodies PLC Approval of grant funding |
| 11/4/2025 | 10:40 | UK RNS | Fusion Antibodies PLC Holding(s) in Company |
| 10/4/2025 | 12:47 | UK RNS | Fusion Antibodies PLC Holding(s) in Company |
| 07/4/2025 | 12:35 | UK RNS | Fusion Antibodies PLC Result of General Meeting |
Fusion Antibodies (FAB) Share Charts1 Year Fusion Antibodies Chart |
|
1 Month Fusion Antibodies Chart |
Intraday Fusion Antibodies Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 22/5/2025 | 10:24 | ☆ Fusion Antibodies: from discovery to Clinical supply ☆ | 4,861 |
| 06/1/2025 | 09:33 | Upcoming Discovery Company Webinar with ShareSoc and InvestorHub | 9 |
| 28/11/2023 | 16:25 | NEW FAB Fusion Antibodies The Next AVCT | 64 |
| 18/9/2020 | 15:23 | Fusion Antibody II | 51 |
| 17/9/2020 | 09:25 | COVID. RAPID PROGRESS MADE. Ј3M RAISED | 58 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 09:59:41 | 6.98 | 7 | 0.49 | O |
| 09:51:44 | 6.98 | 7 | 0.49 | O |
| 09:51:29 | 6.96 | 18,879 | 1,313.96 | O |
| 09:41:48 | 6.70 | 7,571 | 507.62 | O |
| 09:27:06 | 6.98 | 17,199 | 1,199.97 | O |
| Top Posts |
|---|
Posted at 06/5/2025 19:47 by troutisout thiopia,The placing was done at the closing price (and actually that seemed to be manufactured up at the end of that day to fit), the vast majority of the placing shares went to two large IIs, if they were going to do a placing then surely that is the best we could ask for. We have all had a chance to add below that placing price, so there should be no grievances about PIs being missed out. From today's statement, they explain an example of the slippage (or scientific attrition is the way they describe it), if you look back at that example and the previous contract (this was a separate follow on), you'll see the initial contract saw $1.83m of revenue and this follow up was due to see FAB generating $650k of fees by March 2025. They say today in reality due to the project being paused by the client (even FAB don't seem sure if it has ceased entirely), they only received $293k of fees from the follow on project. That left them with a shortfall of $357k, how that would have made a difference to the figures in today's update. Unfortunately that is what happens when you are a CRO, you are contracted by other Biotech/Pharma companies and there is always a risk, that things change down the line. I hold HVO and PYC, lumpy contracts and slippage are part and parcel of that business. We don't know when FAB were told abut the project ceasing (again they didn't seem too sure in today's update) or when it paused, but I am prepared to cut them some slack on this, especially as they state they are working on other things with the same client, so the reasoning is unlikely to be FAB's competency. With that one example, if things were different and the project continued to fruition then we would have had nearly £2.3m in revenue for FY 2025, beating market expectations and no doubt better EBITDA margins. As I said this morning the OptiMAL validation will be a huge boost and it seems they are well on the way to getting this. It's a STRONG BUY for me (although I won't be buying as I have a self imposed rule about being notifiable) |
Posted at 08/4/2025 09:48 by jaknife bri15,"With the placing and the grant funding the company has over £2 million, that is enough cash for over a year,plus up to £5 million for equipment,all we need now is some good news to push the share price up, which will come,Adrian will see to that,this company is going to expand rapidly and increase contracts and revenue, guaranteed." More importantly you need the business to move to breakeven and to stop burning cash. The gross profit margin from the interims was 27% whilst annualised admin expenses are c. £2.3m. Hence you need headline revenue to increase to about £8.5m (£2.3m / 27%) just for the business to get to a break even level. Given that revenues at the interim stage were just £1.2m then that requires a huge leap of c. 250% in revenue just to get to a break even level (£1.2m annualised = £2.4m and x 3.50 = £8.4m). Has FAB announced £8.4m worth of contracts so far this year? JakNife |
Posted at 18/3/2025 07:26 by troutisout I felt something was odd, it’s the share dropping on no real selling, yesterday was weird the MMS dropped it on a delayed sell and then the spread finished where the share price ended the day where it started…. The placing price!Not upset by that though 6.75p is a good price to raise for investors and no point going along at 56 mph trying to conserve the fuel when we can go along at 70mph now our tank has been refuelled. |
Posted at 10/3/2025 10:08 by gtc1508 I asked Chat GPTs deep research function to consider what validation of Optimal might do to FABs valuation.Very very interesting. Remember NOT ADVICE Do your own research and chat gpt can obvs have some inaccuracies: “If Fusion Antibodies’ OptiMAL® platform validation is successful, the share price could surge in the next 2–3 months, with the magnitude depending on validation strength, market sentiment, and commercial traction. Three potential scenarios follow: ⸻ 1. Base Case (2–3x Increase, ~15–25p) If validation confirms OptiMAL® delivers high-quality antibodies faster and more effectively than existing methods, the stock could double or triple in value. Key Drivers: • Strong validation results increase investor confidence in commercial adoption. • Fusion’s low market cap (~£7-8m) means even modest revenue expectations can drive a large re-rating. • Increased demand from retail and institutional investors ahead of potential deals. ⸻ 2. Bull Case (5–7x Increase, ~35–50p) If Fusion validates OptiMAL® and secures commercial traction, such as: • Licensing agreement with a major pharma/biotech. • Multiple paid contracts from biotech clients. • Strategic investment/partnersh Key Drivers: • Market re-rates Fusion as a technology leader, not just a CRO. • Institutional investors and retail momentum drive price growth. • Broker price targets rise, attracting new buyers. Given Fusion traded above 100p pre-2022 (without validation), a 5–7x increase is feasible if OptiMAL® is seen as a game-changer. ⸻ 3. Extreme Bull Case (10x+ Increase, ~75–100p+) If validation proves OptiMAL®’s superiority and triggers major deals, Fusion could transform into a high-growth AI-driven antibody discovery company, comparable to firms like FairJourney (€900m valuation). Key Drivers: • Rapid industry adoption of OptiMAL® as a must-have tool. • Large upfront payment from a licensing deal. • Institutional investors and hedge funds drive a short squeeze. • AI and biotech traders fuel a retail frenzy. In this case, Fusion could skyrocket to 75–100p+ within months as it shifts from a CRO to a proprietary tech platform. ⸻ Final Thoughts – Realistic Expectations • Base Case (~15–25p) is very achievable. • Bull Case (~35–50p) is possible with swift commercial deals. • Extreme Bull Case (~75–100p) requires multiple major deals and a drastic shift in investor perception. Key Factor: Commercial traction—If Fusion proves OptiMAL® works AND lands revenue-generating deals, it could become one of AIM’s biggest biotech comeback stories.” |
Posted at 06/1/2025 14:24 by fillipe Looks like a small number of large (up to 100k shares) sells have knocked the FAB price, for the moment.f |
Posted at 02/1/2025 22:02 by thiopia It's quite a bizarre claim.The main venues for ramping to the masses / great unwashed tends to Twitter or Telegram groups nowadays. There are hardly any posts on Twitter (the few who are promotional get zero to little engagement). I'm not aware of any Telegram group for FAB. As mentioned here there were hardly any posts on FAB on this thread this morning as it was moving. Part of the investment case for FAB that attracted me was the fact it was Unloved Underowned Undervalued as demonstrated by a long flat basing pattern in the share price. Not the sort of stock which appeals to rampers who love volatility. |
Posted at 02/1/2025 09:00 by gtc1508 What Adrian said:“ I don't think there is another company that has quite the technologies that Fusion has. We have a number of different offerings most other companies only have maybe one. So we're really well positioned in that regard. Answering the question how much should it be worth right now, well many times what it is today, multiples of what it is today. it’s clearly undervalued and it has been for quite at some time. in my opinion the the main reason for this seems to have been the perception that we weren't going to survive. Well we're still here. Not only that but we're now thriving we’re fitter, we're better than we were before. Alternatively maybe we would survive but we were going to require significant amounts of additional investment and dilute everybody out and probably in this Marketplace at a lower-price. That is clearly outdated and ill- founded in terms of an assessment. We don't need the money, we have no plans for an investment raise so I think those people have got it wrong and the impact on the share price is wrong and it needs correcting and we need to take that depression that's been on the share price away. I hope that the information that we shared today helps in doing that because clearly we are worth an awful lot more than the market has been suggesting.” |
Posted at 14/12/2024 07:44 by bri15 Yesterday's drop was too good an opportunity to top up,glad you did ijd,i also put a few thousand more in and very happy to hold this one long term as only up share price is heading,as I posted earlier this is a multi billion $ market and big returns to be made, wish I could just switch off for 6 months and not watch daily share price movement as I know we will be far higher in price come the summer. |
Posted at 12/12/2024 19:36 by thiopia some snippets from ShareScope webinarGheko Posts: 991 Price: 6.90 Strong Buy Webinar Today 18:15 Great webinar presentation. A few takeaways for me. 1. The work around Optimal and Optiphage platforms. They could potentially be licensed to every biotech company in THE WORLD!! Hello, all aboard. 2.slip of the tongue when talking about the work with US National Cancer Institute. I got sense that they know it is a done deal. If that announcement comes then add then add an immediate 0 to the share price! 3. As a result of the grant funding where FAB are not paying for the equipment or upkeep they can look to grow margins. 4. When asked about potential news in next 3-6 months naturally very coy but I sensed he looking forward to lots of news. 5. Final comment was the grant gives FAB quote ‘a remarkable opportunity’. Very happy with my investment and adding more tomorrow. |
Posted at 07/12/2024 11:31 by thiopia re 4214My thinking is they have had an initial informal approach from a much larger enterprise The larger enterprise want to keep all the talent on board so have made a friendly approach with a nudge nudge wink wink message something to the effect of "We'd like to buy you out but we can see your share price is nowhere near a level where you could recommend a takeover to your shareholders so we'll give you 1 year to get the share price up and then we'll offer you a premium over the 30 or 90 day Moving Average" In the meantime it gives Management etc all a chance to load up on stock and options That is my guesswork because the Management seem so confident right now and have been buying stock across the Board at regular intervals So either they know a much bigger Company is waiting in the wings or there is some operational development about to happen which should transform company US NCI platform validation and further collaboration or milestones/royalties on an antibody ? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
